One of the therapeutic approaches tried for OPA1-related mitochondrial diseases is genome editing using small ribonucleoprotein particle U1 (U1 snRNP), especially since 30% of OPA1 pathogenic variants are splice-site [99]. The gene discussed is OPA1; the disease is inborn mitochondrial metabolism disorder.